Glucose Health, Inc. Receivables Turnover Ratio (GLUC), from the third quarter 2017 to the third quarter 2016 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Glucose Health, Inc.  (GLUC)
 

Glucose Health Accounts Receivables Turnover Ratio from the third quarter 2017 to the third quarter 2016

Quarterly Results, Trends, Rankings, Statistics


Glucose Health, Inc.'s ability to collect its outstanding accounts receivable from its corporate clients, has improved in the third quarter 2017 to a ratio of 8.99, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the third quarter 2017. Average receivable collection period, for the Glucose Health in Sep 30 2017 quarter, has decreased to 41 days, compared to 58 days, in the Jun 30 2017 quarter.

If we take a look into Healthcare sector 9 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Sep 30 2017 from 0 to 135.

What is Receivable Turnover Ratio?
What is Glucose Health, Inc. Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GLUC Receivables Turnover Ratio (Sep 30 2017)
III. Quarter		 (Jun 30 2017)
II. Quarter		 (Mar 31 2017)
I. Quarter		 (Dec 31 2016)
IV. Quarter		 (Sep 30 2016)
III. Quarter
Y / Y Receivable Change -24.12 % -94.78 % 175.2 % 234.29 % 421.74 %
Y / Y Revenue Change 1027.16 % -88.49 % 12492.5 % 826.22 % 2.68 %
Receivable Turnover Ratio (TTM) 8.99 6.31 6.5 6.4 6.39
GLUC's Total Ranking # 135 # 0 # 0 # #
Accounts Receivable average collection period days 41 58 56 57 57
Seq. Receivable Change 3.52 % -8.69 % -17.68 % -2.5 % -92.88 %
Seq. Revenue Change -30.14 % 125.31 % -0.52 % 619.91 % -99.29 %


Receivable Turnover Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 0
Healthcare Sector # 10
Overall Market # 135

Receivable Turnover Ratio Statistics
High Average Low
4.33 3.08 0.16
(Mar 31 2017)   (Mar 31 2016)





GLUC Company Profile • Back to GLUC Efficiency Comparisons • Compare GLUC Receivables Turnover Ratio to its Competitors

Financial Statements
Glucose Health's Accounts Receivable $ 0 Millions Visit GLUC's Balance sheet
Glucose Health's Sales TTM $ 0 Millions Visit GLUC's Income Statement
Sources of GLUC's Revenues Visit GLUC's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
GLUC's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
GLUC's Growth Rates GLUC's Roa GLUC's Inventory Turnover Ratio GLUC's Dividend Comparisons
GLUC's Profitability Ratios GLUC's Roi GLUC's Asset Turnover Ratio GLUC's Dividend Growth
GLUC's Valuation Ratios GLUC's Roe GLUC's Financial Strength Ratios GLUC's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2017, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Sep 30 2017 Receivable at quarter ending Sep 30 2017
Biocorrx Inc   26.41 $ 0.608  Millions$ 0.023  Millions
Agios Pharmaceuticals Inc   26.23 $ 55.860  Millions$ 2.130  Millions
Dna Testing Centers Corp  24.44 $ 0.055  Millions$ 0.002  Millions
Adaptimmune Therapeutics Plc  23.87 $ 42.099  Millions$ 1.764  Millions
Natera Inc   23.38 $ 206.473  Millions$ 8.831  Millions
Guided Therapeutics Inc   23.11 $ 0.260  Millions$ 0.011  Millions
Eyepoint Inc   23.07 $ 7.647  Millions$ 0.332  Millions
Ernexa Therapeutics Inc   21.52 $ 21.958  Millions$ 1.020  Millions
Neurometrix Inc   20.51 $ 15.878  Millions$ 0.774  Millions
Nuvalent Inc   19.88 $ 3.450  Millions$ 0.174  Millions
Cardiff Lexington Corporation  19.60 $ 1.708  Millions$ 0.087  Millions
Durect Corp  19.51 $ 33.149  Millions$ 1.699  Millions
Invitae Corporation  19.41 $ 52.058  Millions$ 2.683  Millions
Cv Sciences Inc   19.29 $ 16.377  Millions$ 0.849  Millions
Bioxytran Inc   18.93 $ 0.217  Millions$ 0.011  Millions
Kushco Holdings Inc   18.76 $ 18.799  Millions$ 1.002  Millions
Cytokinetics Incorporated  18.61 $ 46.524  Millions$ 2.500  Millions
Opiant Pharmaceuticals Inc   18.50 $ 17.347  Millions$ 0.938  Millions
Kadmon holdings inc   18.48 $ 15.077  Millions$ 0.816  Millions
Regenxbio Inc   18.32 $ 10.049  Millions$ 0.549  Millions
United Cannabis Corp  17.21 $ 0.464  Millions$ 0.027  Millions
Editas Medicine Inc   17.20 $ 10.959  Millions$ 0.637  Millions
Skinvisible Inc   16.67 $ 0.141  Millions$ 0.008  Millions
Immune Design Corp.  16.43 $ 8.768  Millions$ 0.534  Millions
Dyne Therapeutics Inc   16.43 $ 6,977.000  Millions$ 424.750  Millions
Timber Pharmaceuticals Inc   16.24 $ 0.069  Millions$ 0.004  Millions
Caredx Inc   15.03 $ 46.680  Millions$ 3.105  Millions
Aptevo Therapeutics Inc   14.90 $ 27.847  Millions$ 1.869  Millions
Jaguar Health Inc   14.67 $ 2.848  Millions$ 0.194  Millions
Oncomed Pharmaceuticals Inc  14.59 $ 23.733  Millions$ 1.626  Millions

Date modified: 2026-09-08T15:09:00+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.